$18.5 million donation received for cancer research
Cancer Prevention and Research Institute of
$18.5 million to UT Southwestern investigators for cancer studies
DALLAS – The Cancer Prevention and Research Institute of Texas awarded more than $18.5 million to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit a pre-eminent cancer investigator.
As a result of the many excellent proposals submitted by its faculty, which were evaluated through a rigorous peer-review process, UT Southwestern received the most funding of any selected
The $61 million in funding announced Jan. 20 represents the inaugural grants of the $3 billion to be invested in cancer research in
UT Southwestern’s total funding includes nearly $16.5 million to support 18 research projects, including two high impact/high risk projects; $2 million to recruit the first CPRIT Scholar in Cancer Research to the medical center; and $67,000 for three planning grants.
“From investigating the root causes of cancer, to developing novel ways of detecting the disease, to testing promising therapies, our researchers are at the forefront of basic discovery and translation of laboratory findings to clinical practice,” said Dr. Daniel K. Podolsky, president of UT Southwestern. “These grants recognize the leading role that scientists here play in driving advances in cancer care.”
Dr. James Willson, director of the
The breakdown of the grants to UT Southwestern includes:
· $2 million, awarded in December, to recruit Dr. Ralf Kittler as the first CPRIT Scholar in Cancer Research. Dr. Kittler, who will become assistant professor in the Eugene McDermott Center for Human Growth and Development on Feb. 1, focuses his research on discovering diagnostic and therapeutic targets that can be used for the detection, staging and treatment of cancer, especially prostate cancer. This CPRIT award is designed to recruit promising early-career investigators to
· Almost $400,000 to two faculty members in high impact/high risk grants, designated for short-term projects that are developmental or exploratory in nature. They are: Dr. Ralph DeBerardinis, assistant professor of pediatrics – Can glioblastoma growth be suppressed by targeting glutamine metabolism? $200,000; and Dr. Joseph Ready, associate professor of biochemistry – Understanding the activity of a potent anticancer agent, $198,947.
· $67,000 to three faculty members in small planning grants to support coordination of projects involving multiple investigators. They are: Dr. David Chen, professor of radiation oncology – DNA double-strand break repair and genome stability, $25,000; Dr. Jerry Shay, professor of cell biology – Apply genomics and HTP techs to prevent/treat colon cancer, $17,000; and Dr. Dean Sherry, director of the Advanced Imaging Research Center – Center for probe development and commercialization, $25,000.
Eight faculty members each received individual research grants of more than $1 million:
· Dr. Paul Blount, associate professor of physiology – Imaging cancerous tissues with liposomal MRI contrast agents that utilize bioengineered nanovalves, $1,144,531.
· Dr. Kevin Gardner, professor of biochemistry and pharmacology – Discovery and optimization of natural and artificial ligands regulating Hypoxia Inducible Factor, $1,555,050.
· Dr. Jin Jiang, professor of developmental biology and pharmacology – Dissecting the Hippo tumor suppressor pathway in organ size control and stem cell proliferation, $1,130,245.
· Dr. Lawrence Lum, assistant professor of cell biology – A molecularly targeted anticancer therapeutic strategy premised upon attack of aberrant Wnt pathway responses, $1,241,746.
· Dr. Craig Malloy, medical director of the Advanced Imaging Research Center and professor of internal medicine and radiology – Texas A&M-UT Southwestern partnership for cancer imaging and spectroscopy at 7 Tesla, $1,173,255.
· Dr. Luis Parada, chairman of developmental biology – Genetic mouse models of glioma: translational tools for therapeutic development, $1,077,679.
· Dr. Lani Wu, associate professor of pharmacology – Relating drug resistance and tumor microenvironment to cancer cell heterogeneity, $1,238,551.
· Dr. Chengcheng Zhang, assistant professor of physiology and developmental biology – The role of IGFBP2 in acute myeloid leukemia, $1,221,879.
Visit http://www.utsouthwestern.org/cancercenter to learn more about UT Southwestern’s clinical services for cancers.